<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920101</url>
  </required_header>
  <id_info>
    <org_study_id>NDMC570</org_study_id>
    <nct_id>NCT00920101</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging</brief_title>
  <official_title>Effect of Atorvastatin on Inflammatory Atherosclerotic Plaques Assessed by FDG-PET Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Defense Medical College, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Defense Medical College, Japan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether HMG-CoA reductase inhibitor, atorvastatin
      attenuates inflammation in atherosclerotic plaques detected by 18F-fluorodeoxyglucose(FDG)
      PET.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized uptake value (SUV) of 18-FDG detected in carotid/aortic atherosclerotic plaques</measure>
    <time_frame>Baseline and 3 months after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated vasodilation of brachial artery determined by ultrasonography</measure>
    <time_frame>Baseline and 3 months after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum markers for inflammation such as high-sensitive CRP, IL-6 or soluble ICAM-1</measure>
    <time_frame>Baseline and 3 months after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum and urine markers for anti- or pro-oxidant stress such as oxidized LDL or 8-Hydroxydeoxyguanosine</measure>
    <time_frame>Baseline and 3 months after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Max-intima-media thickness (Max-IMT), Mean-IMT and plaque score determined by carotid artery ultrasonography</measure>
    <time_frame>Baseline and 3 months after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipids such as total cholesterol, LDL-cholesterol, HDL-cholesterol, RLP-cholesterol and triglycerides</measure>
    <time_frame>Baseline and 3 months after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle counseling</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle counseling</intervention_name>
    <description>Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.</description>
    <arm_group_label>Lifestyle counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with accumulation of FDG-PET in carotid artery or aorta

        Exclusion Criteria:

          -  LDL cholesterol level (calculated by using Friedewald formula) higher than 180 mg/dl
             or less than 120 mg/dl

          -  subjects currently taking HMG CoA-reductase (Statins) or fibrates

          -  symptomatic coronary artery diseases

          -  symptomatic cerebrovascular diseases

          -  subjects suffered from myocardial infarction or stroke within 6 months

          -  subjects underwent percutaneous vascular interventions or vascular operations within 6
             months

          -  diabetic patients with poor glycemic control (HbA1c&gt;8.5)

          -  hypertensive patients with poor blood pressure control

          -  subjects with neoplasms

          -  subjects with systemic inflammatory diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsunori Ikewaki</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Defense Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Makoto Ayaori, MD</last_name>
    <phone>81429951617</phone>
    <email>ayaori@ndmc.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harumi Kondo, PhD</last_name>
    <phone>81429951617</phone>
    <email>harumi@ndmc.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Defense medical College</name>
      <address>
        <city>Tokotozawa</city>
        <state>Saitama</state>
        <zip>359-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Makoto Ayaori, MD</last_name>
      <phone>81429951617</phone>
      <email>ayaori@ndmc.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <last_update_submitted>March 11, 2013</last_update_submitted>
  <last_update_submitted_qc>March 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Defense Medical College, Japan</investigator_affiliation>
    <investigator_full_name>Makoto Ayaori</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>atherosclerotic plaques</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>HMG-CoA reductase inhibitor</keyword>
  <keyword>statin</keyword>
  <keyword>lipid-lowering therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

